Once daily Busulfan (Bu) and fludarabine (Flu) with allogeneic stem cell transplantation (AlloSCT) in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS): Clinical results and pharmacokinetics.

被引：0
|
作者：
de Lima, M
Madden, T
Couriel, D
Thall, RF
Shahjahan, M
Giralt, S
Anderlini, P
Russell, J
Shpall, EJ
Champlin, RE
Andersson, BS
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantation, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2607
引用
收藏
页码：704A / 705A
页数：2
相关论文
共 50 条
  • [1] Allogeneic transplantation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) using a low-toxicity combination of intravenous (IV) Busulfan (Bu) and Fludarabine (Flu) ±ATG.
    De Lima, M
    Couriel, D
    Shahjahan, M
    Madden, T
    Gajewski, J
    Giralt, S
    Russell, J
    Champlin, RE
    Andersson, BS
    BLOOD, 2002, 100 (11) : 853A - 853A
  • [2] Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    de Lima, M
    Couriel, D
    Thall, PF
    Wang, XM
    Madden, T
    Jones, R
    Shpall, EJ
    Shahjahan, M
    Pierre, B
    Giralt, S
    Korbling, M
    Russell, JA
    Champlin, RE
    Andersson, BS
    BLOOD, 2004, 104 (03) : 857 - 864
  • [3] BUSULFAN FLUDARABINE (BU-FLU) COMPARED TO THIOTEPA BUSULFAN FLUDARABINE (TBF) FOR ALLOGENEIC TRANSPLANTS IN ACUTE MYELOID LEUKEMIA (AML) IN REMISSION
    Sora', F.
    Chiusolo, P.
    Di Grazia, C.
    Raiola, A. M.
    Bregante, S.
    Mordini, N.
    Olivieri, A.
    Iori, A. P.
    Patriarca, F.
    Grisariu, S.
    Terrazzi, E.
    Rambaldi, A.
    Sica, S.
    Angelucci, E.
    Bacigalupo, A.
    HAEMATOLOGICA, 2019, 104 : 133 - 133
  • [4] A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
    Andersson, Borje S.
    Thall, Peter F.
    Ma, Junsheng
    Valdez, Benigno C.
    Bassett, Roland, Jr.
    Chen, Julianne
    Ahmed, Sairah
    Alousi, Amin
    Bashir, Qaiser
    Ciurea, Stefan
    Gulbis, Alison
    Cool, Rita
    Kawedia, Jitesh
    Hosing, Chitra
    Kebriaei, Partow
    Kornblau, Steve
    Myers, Alan
    Oran, Betul
    Rezvani, Katayoun
    Shah, Nina
    Shpall, Elizabeth
    Parmar, Simrit
    Popat, Uday R.
    Nieto, Yago
    Champlin, Richard E.
    BONE MARROW TRANSPLANTATION, 2022, 57 (08) : 1295 - 1303
  • [5] A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
    Borje S. Andersson
    Peter F. Thall
    Junsheng Ma
    Benigno C. Valdez
    Roland Bassett
    Julianne Chen
    Sairah Ahmed
    Amin Alousi
    Qaiser Bashir
    Stefan Ciurea
    Alison Gulbis
    Rita Cool
    Jitesh Kawedia
    Chitra Hosing
    Partow Kebriaei
    Steve Kornblau
    Alan Myers
    Betul Oran
    Katayoun Rezvani
    Nina Shah
    Elizabeth Shpall
    Simrit Parmar
    Uday R. Popat
    Yago Nieto
    Richard E. Champlin
    Bone Marrow Transplantation, 2022, 57 : 1295 - 1303
  • [6] Fludarabine (Flu) and IV busulfan (Bu)±ATG:: Low toxicity conditioning regimen for stem cell transplantation (SCT) in AML and MDS -: Preliminary results.
    deLima, M
    Shahjahan, M
    Madden, T
    Tran, HT
    Gajewski, JL
    Couriel, DR
    Giralt, S
    Donato, ML
    Anderlini, P
    Korbling, M
    Khouri, I
    Russell, JA
    Champlin, RE
    Andersson, BS
    BLOOD, 2001, 98 (11) : 345B - 345B
  • [7] A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS
    Andersson, Borje S.
    Thall, Peter
    Valdez, Benigno C.
    Ma, Junsheng
    Chen, Julianne
    Ahmed, Sairah
    Alousi, Amin M.
    Bashir, Qaiser
    Ciurea, Stefan O.
    Gulbis, Alison
    Hosing, Chitra
    Jones, Roy B.
    Kawedia, Jitesh
    Kebriaei, Partow
    Kornblau, Steven M.
    Myers, Alan
    Oran, Betul
    Rezvani, Katayoun
    Shah, Nina
    Shpall, Elizabeth J.
    Parmar, Simrit
    Popat, Uday R.
    Nieto, Yago
    Champlin, Richard E.
    BLOOD, 2020, 136
  • [8] Allogeneic stem cell transplantation with busulfan (BU)/cytoxan(CY) versus BUCY/VP-16 for acute myelogenous leukemia (AML).
    George, R
    Boparai, N
    Bolwell, B
    Kalaycio, M
    BLOOD, 1999, 94 (10) : 383B - 383B
  • [9] Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
    Chikako Ohwada
    Shingo Yamazaki
    Katsuhiro Shono
    Kensuke Kayamori
    Yutaro Hino
    Nagisa Oshima-Hasegawa
    Tomoya Muto
    Shokichi Tsukamoto
    Shio Mitsukawa
    Yusuke Takeda
    Naoya Mimura
    Masahiro Takeuchi
    Tohru Iseki
    Masahiro Onoda
    Akira Yokota
    Takaaki Suzuki
    Itsuko Ishii
    Chiaki Nakaseko
    Emiko Sakaida
    International Journal of Hematology, 2021, 114 : 664 - 673
  • [10] Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation
    Ohwada, Chikako
    Yamazaki, Shingo
    Shono, Katsuhiro
    Kayamori, Kensuke
    Hino, Yutaro
    Oshima-Hasegawa, Nagisa
    Muto, Tomoya
    Tsukamoto, Shokichi
    Mitsukawa, Shio
    Takeda, Yusuke
    Mimura, Naoya
    Takeuchi, Masahiro
    Iseki, Tohru
    Onoda, Masahiro
    Yokota, Akira
    Suzuki, Takaaki
    Ishii, Itsuko
    Nakaseko, Chiaki
    Sakaida, Emiko
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (06) : 664 - 673
12345